Related Experiment Video

Updated: Sep 21, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction

Hasan Ali Barman1, Selim Tanyolaç1, Omer Dogan2

  • 1Department of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpaşa, Haseki Street No:32, 34096, Fatih/İstanbul, Turkey.

Clinical Drug Investigation
|May 31, 2022
PubMed

Insights

Sacubitril/valsartan treatment in heart failure with reduced ejection fraction patients significantly lowered cholesterol and triglyceride levels. High-density lipoprotein cholesterol also improved, regardless of statin use.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor proven to reduce cardiovascular mortality in heart failure with reduced ejection fraction (HFrEF).
  • The impact of sacubitril/valsartan on lipid profiles in HFrEF patients requires further investigation.

Purpose of the Study:

  • To evaluate the long-term effects of sacubitril/valsartan on lipid parameters in patients with HFrEF.
  • To assess changes in total cholesterol, HDL cholesterol, and triglycerides over three years of treatment.

Main Methods:

  • A single-center retrospective cross-sectional study included 192 HFrEF patients (NYHA II-V) on sacubitril/valsartan.
  • Lipid levels and NT-proBNP were measured at 3-month intervals for up to three years.
  • Data analysis compared baseline lipid levels with those at the third year.

Main Results:

  • Sacubitril/valsartan use led to a significant decrease in total cholesterol (196.1 to 161.5 mg/dL, p < 0.001) and triglycerides (159.1 to 121.4 mg/dL, p < 0.001).
  • High-density lipoprotein cholesterol levels significantly improved (44.9 to 48.2 mg/dL, p < 0.001).
  • These lipid changes were observed independently of concurrent statin therapy.

Conclusions:

  • Sacubitril/valsartan therapy in HFrEF patients is associated with favorable long-term changes in lipid profiles.
  • The drug may decrease total cholesterol and triglycerides while improving HDL cholesterol.
  • These findings suggest a potential pleiotropic benefit of sacubitril/valsartan beyond its primary hemodynamic effects.
Abstract

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
506
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
447
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
42
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
67